Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study.

Abstract

BACKGROUND:

Statins may have anti-inflammatory and immunomodulatory effects that could reduce the risk of mortality from influenza virus infections.

METHODS:

The Centers for Disease Control and Prevention's Emerging Infections Program conducts active surveillance for persons hospitalized with laboratory-confirmed influenza in 59 counties in 10 states. We analyzed data for hospitalized adults during the 2007-2008 influenza season to evaluate the association between receiving statins and influenza-related death.

RESULTS:

We identified 3043 patients hospitalized with laboratory-confirmed influenza, of whom 1013 (33.3%) received statins and 151 (5.0%) died within 30 days of their influenza test. Patients who received statins were more likely to be older, male, and white; to suffer from cardiovascular, metabolic, renal, and chronic lung disease; and to have been vaccinated against influenza that season. In a multivariable logistic regression model, administration of statins prior to or during hospitalization was associated with a protective odds of death (adjusted odds ratio, 0.59 [95% confidence interval, .38-.92]) when adjusting for age; race; cardiovascular, lung, and renal disease; influenza vaccination; and antiviral administration.

CONCLUSIONS:

Statin use may be associated with reduced mortality in patients hospitalized with influenza.

• Authors: Meredith L Vandermeer, Ann R Thomas, Laurie Kamimoto, Arthur Reingold, Ken Gershman, James Meek, Monica M Farley, Patricia Ryan, Ruth Lynfield, Joan Baumbach, William Schaffner, Nancy Bennett, Shelley Zansky
• Journal: The Journal of infectious diseases (J Infect Dis) Vol. 205 Issue 1 Pg. 13-9 (Jan 01 2012) ISSN: 1537-6613 [Electronic] United States
• PMID: 22170954 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Hydroxymethylglutaryl-CoA Reductase Inhibitors

Topics

• Aged
• Aged, 80 and over
• Female
• Hospital Mortality
• Hospitalization
• Humans
• Hydroxymethylglutaryl-CoA Reductase Inhibitors (therapeutic use)
• Influenza, Human (drug therapy, mortality)
• Logistic Models
• Male
• Middle Aged
• Odds Ratio
• Population Surveillance
• United States (epidemiology)